AG
ALXN

Artal Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Artal Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,000
Closed -$12.2M – 124
2017
Q2 		$12.2M Hold
100,000
– – 0.21% 32
2017
Q1 		$12.1M Sell
100,000
-100,000
-50% -$12.9M 0.27% 34
2016
Q4 		$24.5M Buy
+200,000
New +$24.5M 0.54% 21

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Artal Group's ALXN Position: Q3 2017 in Review

Artal Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 100,000 shares — an estimated $12.2M sold.

Artal Group first reported a position in ALXN in Q4 2016 and held it in 3 quarters. The position peaked at $24.5M in Q4 2016. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Artal Group reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Artal Group sold 100,000 Alexion Pharmaceuticals shares in Q3 2017, an estimated $12.2M.
  • Artal Group first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Artal Group's Alexion Pharmaceuticals position peaked at $24.5M in Q4 2016.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.